Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Inhibitors & Agonists > Others

Others

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC2407 Gsk-756619
Novel Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor
More description
DCC2406 Gsk729
Novel potent inhibitor of EchA6
More description
DCC2405 Gsk716
Novel stabilizer of Zα 1 -antitrypsin, blocking Zα 1 -antitrypsin polymerisation in vitro, reducing intracellular polymerisation and increasing the secretion of Zα 1 -antitrypsin threefold in an iPSC model of disease
More description
DCC2404 Gsk702
Negative control for GSK699
More description
DCC2403 Gsk699
Novel PCAF/GCN5 degrader, modulating PCAF/GCN5 immune cell function through a PROTAC approach
More description
DCC2402 Gsk6776
Novel, soluble, permeable, and selective BRD7/9 inhibitor
More description
DCC2401 Gsk635416a
Novel ATM inhibitor with cancer cell specific radiosensitization activity
More description
DCC2400 Gsk579289a
Potent polo-like kinase 1 (PLK1) inhibitor
More description
DCC2399 Gsk5750
Novel inhibitor of the Ribonuclease H Activity of HIV-1 Reverse Transcriptase
More description
DCC2398 Gsk572a
Novel potent EchA6 inhibitor
More description
DCC2397 Gsk557296
Novel highly potent and selective non-peptide oxytocin receptor antagonist
More description
DCC2396 Gsk466317a
Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)
More description
DCC2395 Gsk452
Novel, Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitor
More description
DCC2394 Gsk41364a
Novel specific inhibitor of polo-like kinase 1 (PLK-1), inducing cell death by causing cell cycle arrest at G2/M phase by competing with the ATP binding site of PLK-1 thus leading to apoptosis
More description
DCC2393 Gsk4028
Negative control for GSK4027
More description
DCC2392 Gsk-3ß/hdac Inhibitor C11
First-in-Class GSK-3β/HDAC Dual Inhibitor as a Disease-Modifying Agent To Combat Alzheimer’s Disease
More description
DCC2391 Gsk3-in-40
Potent and irreversible inhibitor of GSK3
More description
DCC2389 Gsk3i Xv
Novel highly potent cell-permeable, reversible, ATP-competitive inhibitor of GSK-3 (IC50 = 0.4 and 0.6 nM for GSK-3α and GSK-3β, respectively)
More description
DCC2388 Gsk3830052
Novel DNMT1-selective inhibitor (IC 50 = 0.11 ± 0.02 µM)
More description
DCC2387 Gsk366a
Novel anti-TB agent against Mycobacterium tuberculosis and Mycobacterium bovis BCG, targeting MmpL3 and inhibiting EchA6
More description
DCC2386 Gsk360a
Novel inhibitor of prolyl hydroxylase (PHD) domain-containing enzyme
More description
DCC2385 Gsk-354
Novel lysine specific histone demethylase 1 (LSD1) inhibitor, exhibiting high selectivity to LSD1 over MAOs
More description
DCC2384 Gsk334429
Novel selective non-imidazole histamine H 3 receptor antagonist
More description
DCC2383 Gsk3277329
Novel agonist of toll-like receptor 2 (TLR2), stimulating the release of G-CSF in activated THP-1 cells, peripheral blood mononuclear cells, and human umbilical vein endothelial cells
More description
DCC2382 Gsk3182571
Promiscuous kinase inhibitor, a close analog of CTx-0294885
More description
DCC2381 Gsk317354a
Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)
More description
DCC2380 gsk314181a
Potent and selective antagonist of P2X7 receptor
More description
DCC2379 Gsk3038548a
Novel potent RORγ inverse agonist
More description
DCC2378 Gsk-3008348-n1-methyl
Novel quaternized GSK-3008348 derivative, acting as a highly selective αvβ6 Integrin Inhibitor
More description
DCC2377 Gsk299115a
Novel inhbitor of protein kinase GRK1/2/5 and PKA
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X